Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$39.08 USD
-0.39 (-0.99%)
Updated May 10, 2024 04:00 PM ET
After-Market: $39.10 +0.02 (0.05%) 6:40 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
IONS 39.08 -0.39(-0.99%)
Will IONS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IONS
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for IONS
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Ionis Pharmaceuticals: Advancing Pipeline and Path to Profitability Justify Buy Rating
RBC Capital Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals price target lowered by $3 at Wells Fargo, here's why
Ionis Pharmaceuticals: A Buy Rating with Promising Drug Developments and Market Potential